Search

Your search keyword '"Jarzab, Barbara"' showing total 576 results
Start Over Author "Jarzab, Barbara"
576 results on '"Jarzab, Barbara"'

4. Changing Clinical Presentation of Pediatric Differentiated Thyroid Cancer in Poland: A Retrospective Cohort Study Spanning 45 Years.

Author

Kropinska, Aleksandra, Ledwon, Aleksandra, Paliczka Cieslik, Ewa, Olczyk, Tomasz, Blewaska, Aleksandra, Krzempek, Marcela, Wilk, Agata, Cortez, Alexander, Czarniecka, Agnieszka, Jarzab, Barbara, and Handkiewicz Junak, Daria

Subjects
LYMPHATIC metastasis, CHILDHOOD cancer, SYMPTOMS, DISEASE progression, PAPILLARY carcinoma, THYROID cancer
Abstract

Background: Differentiated thyroid carcinoma (DTC) in children is uncommon; clinical presentation over recent decades is incompletely characterized. Methods: This retrospective cohort study analyzed demographic and disease characteristics of consecutive juveniles with DTC treated from 1970 to 2015 at Poland's largest pediatric DTC referral center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, who had available records. Sex, age, histopathological characteristics, and DTC stage were documented. We aimed to identify changes in these variables over time and independent risk factors for lymph node or distant metastases. Trends in these variables were assessed using the Cochran–Armitage test and Spearman correlation. Multivariable logistic regression was performed to identify risk factors associated with lymph node or distant metastases. Results: 475 of 479 patients (99.2%) were included in the analysis; roughly half were age ≥15 years, 10%, <10 years. Papillary thyroid carcinoma (PTC) represented 88% of cases and follicular thyroid carcinoma (FTC) 11%. Tumors ≤2 cm constituted 56% of cases with relevant data; those >4 cm accounted for 12%. Multifocality was observed in 37% and extrathyroidal invasion in 22%. Lymph node metastases were noted in 59% and distant metastases in 16%. Over the observation period, significant trends among new cases included: increased proportion of adolescents >15 years; increased frequency of tumors ≤2 cm, decreased multifocality rates, and increased proportion of PTC versus FTC. Extrathyroidal invasion rates remained appreciable throughout, ranging from 17 to 28% during the 5-year study subperiods after 1990. Lymph node metastases significantly increased in frequency in the central neck, remaining consistently common in lateral sites; presence of distant metastases significantly decreased. In multivariable analysis, multifocality, extrathyroidal invasion, and tumor size were independently associated with lateral lymph node metastases and multifocality, larger tumor size, and N1b metastases with distant spread. Conclusions: Our observations of a rising proportion of diagnoses in adolescence, reductions in primary tumor size, and decreased frequency of multifocality and distant metastases may reflect increased detection of patients with less aggressive DTC at earlier disease stages. Nonetheless, we found persistently substantial rates of locoregionally advanced disease features (multifocality, extrathyroidal invasion, and lymph node metastases), which multivariable analyses suggested have significant associations with lateral lymph node and/or distant metastases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study

Author

Capdevila, Jaume, primary, Krajewska, Jolanta, additional, Hernando, Jorge, additional, Robinson, Bruce, additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O., additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Williamson, Denise, additional, Levytskyy, Roman, additional, Oliver, Jennifer, additional, Keam, Bhumsuk, additional, and Brose, Marcia S., additional

Published
2024
Full Text
View/download PDF

6. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma

Author

Kim, Kyeong J., Kim, Sin G., Tan, Jie, Shen, Xiaopei, Viola, David, Elisei, Rossella, Puxeddu, Efisio, Fugazzola, Laura, Colombo, Carla, Jarzab, Barbara, Czarniecka, Agnieszka, Lam, Alfred K., Mian, Caterina, Vianello, Federica, Yip, Linwah, Riesco-Eizaguirre, Garcilaso, Santisteban, Pilar, O'Neill, Christine J., Sywak, Mark S., Clifton-Bligh, Roderick, Bendlova, Bela, Sýkorová, Vlasta, and Xing, Mingzhao

Published
2020
Full Text
View/download PDF

8. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study

Author

Castinetti, Frederic, Waguespack, Steven G, Machens, Andreas, Uchino, Shinya, Hasse-Lazar, Kornelia, Sanso, Gabriella, Else, Tobias, Dvorakova, Sarka, Qi, Xiao Ping, Elisei, Rossella, Maia, Ana Luisa, Glod, John, Lourenço, Delmar Muniz, Jr, Valdes, Nuria, Mathiesen, Jes, Wohllk, Nelson, Bandgar, Tushar R, Drui, Delphine, Korbonits, Marta, Druce, Maralyn R, Brain, Caroline, Kurzawinski, Tom, Patocs, Atila, Bugalho, Maria Joao, Lacroix, Andre, Caron, Philippe, Fainstein-Day, Patricia, Borson Chazot, Francoise, Klein, Marc, Links, Thera P, Letizia, Claudio, Fugazzola, Laura, Chabre, Olivier, Canu, Letizia, Cohen, Regis, Tabarin, Antoine, Spehar Uroic, Anita, Maiter, Dominique, Laboureau, Sandrine, Mian, Caterina, Peczkowska, Mariola, Sebag, Frederic, Brue, Thierry, Mirebeau-Prunier, Delphine, Leclerc, Laurence, Bausch, Birke, Berdelou, Amandine, Sukurai, Akihiro, Vlcek, Petr, Krajewska, Jolanta, Barontini, Marta, Vaz Ferreira Vargas, Carla, Valerio, Laura, Ceolin, Lucieli, Akshintala, Srivandana, Hoff, Ana, Godballe, Christian, Jarzab, Barbara, Jimenez, Camilo, Eng, Charis, Imai, Tsuneo, Schlumberger, Martin, Grubbs, Elizabeth, Dralle, Henning, Neumann, Hartmut P, and Baudin, Eric

Published
2019
Full Text
View/download PDF

9. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Author

Leboulleux, Sophie, Kapiteijn, Ellen, Litière, Saskia, Schöffski, Patrick, Godbert, Yann, Rodien, Patrice, Jarzab, Barbara, Salvatore, Domenico, Zanetta, Sylvie, Capdevila, Jaume, Bastholt, Lars, De La Fouchardiere, Christelle, Lalami, Yassine, Bardet, Stéphane, Cornélis, Frank, Dedecjus, Marek, Links, Thera, Sents, Ward, Schlumberger, Martin, and Locati, D. Laura

Subjects
MEDULLARY thyroid carcinoma, TASK forces, CANCER patients, LOG-rank test, OVERALL survival
Abstract

Background: Nintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC). Design: EORTC-1209 (NCT01788982) was a double-blind randomized (2:1 ratio) placebo-controlled phase II, multi-cohort study exploring the efficacy and safety of nintedanib in patients with progressive, locally advanced, and/or metastatic RAIR DTC and MTC. The primary endpoint was progression-free survival (PFS) in the per-protocol (PP) population for both cohorts. Secondary endpoints included response rate, duration of response, overall survival (OS), and safety. Results: RAIR DTC cohort: Seventy out of the 75 planned patients with RAIR DTC (median age, 66 years; 39 women) who had progressed after one (76%) or two lines (24%) of previous systemic therapy were randomized to receive either nintedanib (N = 45) or placebo (N = 25). Of these, 69 patients started treatment and 56 met all inclusion criteria (PP). At data cutoff, the median duration of follow-up was 26.3 months in the nintedanib arm and 19.8 months in the placebo arm. In the PP population, themedian PFS was 3.7 months [80% confidence interval (CI), 1.9-6.5] in the nintedanib arm and 2.9 months (80% CI, 2.0-5.6) in the placebo arm(HR = 0.65; 80% CI, 0.42-0.99; one-sided log-rank test P = 0.0947). No objective response was observed. The median OS was 29.6 months [80% CI, 15.2-not reached (NR)] in the nintedanib arm and not reached in the placebo arm. Grade 3-4 adverse events of any attribution occurred in 50% of patients receiving nintedanib and in 36% of patients receiving placebo. MTC cohort: Thirty-one out of the 67 planned patients with MTC (median age, 57 years; eight women) who had progressed after one (68%) or two (32%) lines of previous systemic therapy were randomized to receive either nintedanib (N = 22) or placebo (N = 9). Of these, 20 patients (15 in the nintedanib arm and five in the placebo arm) started treatment and met all inclusion criteria (PP). The median PFS was 7.0 months (80% CI, 1.9-8.7) in the nintedanib arm and 3.9 months (80% CI, 3.0-5.5) in the placebo arm (HR = 0.49; 95% CI, 0.16-1.53). No objective response was reported. The median OS was 16.4 months (80% CI, 12.1-24.9) in the nintedanib arm and 12.3 months (80% CI, 7.1-NR) in the placebo arm. Grade 3-4 adverse events of any attribution during the blinded period occurred in 59.1% of patients receiving nintedanib and in 33.3% of patients receiving placebo. Conclusion: This study did not suggest a clinically significant improvement of PFS with nintedanib over placebo in patients with pretreated RAIR DTC and MTC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Author

Hadoux, Julien, primary, Elisei, Rossella, additional, Brose, Marcia S., additional, Hoff, Ana O., additional, Robinson, Bruce G., additional, Gao, Ming, additional, Jarzab, Barbara, additional, Isaev, Pavel, additional, Kopeckova, Katerina, additional, Wadsley, Jonathan, additional, Führer, Dagmar, additional, Keam, Bhumsuk, additional, Bardet, Stéphane, additional, Sherman, Eric J., additional, Tahara, Makoto, additional, Hu, Mimi I., additional, Singh, Ravinder, additional, Lin, Yan, additional, Soldatenkova, Victoria, additional, Wright, Jennifer, additional, Lin, Boris, additional, Maeda, Patricia, additional, Capdevila, Jaume, additional, and Wirth, Lori J., additional

Published
2023
Full Text
View/download PDF

11. Medullary Carcinoma

Author

Elisei, Rossella, Jarzab, Barbara, Lenzi, Andrea, Series Editor, Jannini, Emmanuele A., Series Editor, Vitti, Paolo, editor, and Hegedüs, Laszlo, editor

Published
2018
Full Text
View/download PDF

12. Cabozantinib in Progressive Medullary Thyroid Cancer

Author

Elisei, Rossella, Schlumberger, Martin J, Müller, Stefan P, Schöffski, Patrick, Brose, Marcia S, Shah, Manisha H, Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C, Niederle, Bruno, Cohen, Ezra EW, Wirth, Lori J, Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, and Sherman, Steven I

Subjects
Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Anilides, Calcitonin, Carcinoembryonic Antigen, Carcinoma, Neuroendocrine, Disease-Free Survival, Double-Blind Method, Female, Humans, Male, Middle Aged, Protein Kinase Inhibitors, Pyridines, Thyroid Neoplasms, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.Patients and methodsWe conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.ResultsThe estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.ConclusionCabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

Published
2013

15. Data from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Author

Schlumberger, Martin, primary, Jarzab, Barbara, primary, Cabanillas, Maria E., primary, Robinson, Bruce, primary, Pacini, Furio, primary, Ball, Douglas W., primary, McCaffrey, Judith, primary, Newbold, Kate, primary, Allison, Roger, primary, Martins, Renato G., primary, Licitra, Lisa F., primary, Shah, Manisha H., primary, Bodenner, Donald, primary, Elisei, Rossella, primary, Burmeister, Lynn, primary, Funahashi, Yasuhiro, primary, Ren, Min, primary, O'Brien, James P., primary, and Sherman, Steven I., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Author

Schlumberger, Martin, primary, Jarzab, Barbara, primary, Cabanillas, Maria E., primary, Robinson, Bruce, primary, Pacini, Furio, primary, Ball, Douglas W., primary, McCaffrey, Judith, primary, Newbold, Kate, primary, Allison, Roger, primary, Martins, Renato G., primary, Licitra, Lisa F., primary, Shah, Manisha H., primary, Bodenner, Donald, primary, Elisei, Rossella, primary, Burmeister, Lynn, primary, Funahashi, Yasuhiro, primary, Ren, Min, primary, O'Brien, James P., primary, and Sherman, Steven I., primary

Published
2023
Full Text
View/download PDF

21. RAPORT: VII SPOTKANIE RADY EKSPERTÓW DS. CHORÓB RZADKICH MEDYCZNEJ RACJI STANU. REPORT: 7th MEETING OF THE COUNCIL OF EXPERTS FOR RARE DISEASES FOR A MEDICAL REASON

Author

Gierczyński, Jakub, Adamski, Jakub, Chrzanowska, Krystyna, Dwilewicz-Trojaczek, Jadwiga, Dziegielewski, Michal, Hus, Marek, Jarzab, Barbara, Kostera-Pruszczyk, Anna, Latos-Bieleńska, Anna, Malecka-Wojcieszko, Ewa, Meder, Janusz, Mierzejewski, Piotr, Schymalla, Iwona, Michał Sutkowski, Styczynski, Jan, Cegielska, Jolanta Sykut, Wysoczański, Wojciech, Zuber, Zbigniew Michal, and Zurowska, Aleksandra

Published
2023
Full Text
View/download PDF

22. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Author

Brose, Marcia S, Nutting, Christopher M, Jarzab, Barbara, Elisei, Rossella, Siena, Salvatore, Bastholt, Lars, de la Fouchardiere, Christelle, Pacini, Furio, Paschke, Ralf, Shong, Young Kee, Sherman, Steven I, Smit, Johannes W A, Chung, John, Kappeler, Christian, Peña, Carol, Molnár, István, and Schlumberger, Martin J

Published
2014
Full Text
View/download PDF

24. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study

Author

Castinetti, Frederic, Qi, Xiao-Ping, Walz, Martin K, Maia, Ana Luiza, Sansó, Gabriela, Peczkowska, Mariola, Hasse-Lazar, Kornelia, Links, Thera P, Dvorakova, Sarka, Toledo, Rodrigo A, Mian, Caterina, Bugalho, Maria Joao, Wohllk, Nelson, Kollyukh, Oleg, Canu, Letizia, Loli, Paola, Bergmann, Simona R, Costa, Josefina Biarnes, Makay, Ozer, Patocs, Attila, Pfeifer, Marija, Shah, Nalini S, Cuny, Thomas, Brauckhoff, Michael, Bausch, Birke, von Dobschuetz, Ernst, Letizia, Claudio, Barczynski, Marcin, Alevizaki, Maria K, Czetwertynska, Malgorzata, Ugurlu, M Umit, Valk, Gerlof, Plukker, John T M, Sartorato, Paola, Siqueira, Debora R, Barontini, Marta, Szperl, Malgorzata, Jarzab, Barbara, Verbeek, Hans H G, Zelinka, Tomas, Vlcek, Petr, Toledo, Sergio P A, Coutinho, Flavia L, Mannelli, Massimo, Recasens, Monica, Demarquet, Lea, Petramala, Luigi, Yaremchuk, Svetlana, Zabolotnyi, Dmitry, Schiavi, Francesca, Opocher, Giuseppe, Racz, Karoly, Januszewicz, Andrzej, Weryha, Georges, Henry, Jean-Francois, Brue, Thierry, Conte-Devolx, Bernard, Eng, Charis, and Neumann, Hartmut P H

Published
2014
Full Text
View/download PDF

28. Gene signature of the post-Chernobyl papillary thyroid cancer

Author

Handkiewicz-Junak, Daria, Swierniak, Michal, Rusinek, Dagmara, Oczko-Wojciechowska, Małgorzata, Dom, Genevieve, Maenhaut, Carine, Unger, Kristian, Detours, Vincent, Bogdanova, Tetiana, Thomas, Geraldine, Likhtarov, Ilya, Jaksik, Roman, Kowalska, Malgorzata, Chmielik, Ewa, Jarzab, Michal, Swierniak, Andrzej, and Jarzab, Barbara

Published
2016
Full Text
View/download PDF

29. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

Author

Brose, Marcia S., primary, Robinson, Bruce G., additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia‐Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O., additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Sen, Suvajit, additional, Oliver, Jennifer W., additional, Banerjee, Kamalika, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

30. Tackling Thyroid Cancer in Europe—The Challenges and Opportunities

Author

Horgan, Denis, primary, Führer-Sakel, Dagmar, additional, Soares, Paula, additional, Alvarez, Clara V., additional, Fugazzola, Laura, additional, Netea-Maier, Romana T., additional, Jarzab, Barbara, additional, Kozaric, Marta, additional, Bartes, Beate, additional, Schuster-Bruce, James, additional, Dal Maso, Luigino, additional, Schlumberger, Martin, additional, and Pacini, Furio, additional

Published
2022
Full Text
View/download PDF

32. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention

Author

Bausch, Birke, Schiavi, Francesca, Ni, Ying, Welander, Jenny, Patocs, Attila, Ngeow, Joanne, Wellner, Ulrich, Malinoc, Angelica, Taschin, Elisa, Barbon, Giovanni, Lanza, Virginia, Söderkvist, Peter, Stenman, Adam, Larsson, Catharina, Svahn, Fredrika, Chen, Jin-Lian, Marquard, Jessica, Fraenkel, Merav, Walter, Martin A., Peczkowska, Mariola, Prejbisz, Aleksander, Jarzab, Barbara, Hasse-Lazar, Kornelia, Petersenn, Stephan, Moeller, Lars C., Meyer, Almuth, Reisch, Nicole, Trupka, Arnold, Brase, Christoph, Galiano, Matthias, Preuss, Simon F., Kwok, Pingling, Lendvai, Nikoletta, Berisha, Gani, Makay, Özer, Boedeker, Carsten C., Weryha, Georges, Racz, Karoly, Januszewicz, Andrzej, Walz, Martin K., Gimm, Oliver, Opocher, Giuseppe, Eng, Charis, and Neumann, Hartmut P. H.

Published
2017
Full Text
View/download PDF

33. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer

Author

Wang, Fei, Yu, Xiaolong, Shen, Xiaopei, Zhu, Guangwu, Huang, Yueye, Liu, Rengyun, Viola, David, Elisei, Rossella, Puxeddu, Efisio, Fugazzola, Laura, Colombo, Carla, Jarzab, Barbara, Czarniecka, Agnieszka, Lam, Alfred K, Mian, Caterina, Vianello, Federica, Yip, Linwah, Riesco-Eizaguirre, Garcilaso, Santisteban, Pilar, OʼNeill, Christine J, Sywak, Mark S, Clifton-Bligh, Roderick, Bendlova, Bela, Sýkorová, Vlasta, Wang, Yangang, Liu, Shiguo, Zhao, Jiajun, Zhao, Shihua, and Xing, Mingzhao

Published
2017

35. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Author

Durante, Cosimo, primary, Brose, Marcia, additional, Robinson, Bruce, additional, Sherman, Steven I, additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O, additional, Hitre, Erika, additional, Bowles, Daniel W, additional, Sen, Suvajit, additional, Patel, Purvi, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

36. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Author

Capdevila, Jaume, primary, Klochikhin, Arkadiy, additional, Leboulleux, Sophie, additional, Isaev, Pavel, additional, Badiu, Corin, additional, Robinson, Bruce, additional, Hughes, Brett G.M., additional, Keam, Bhumsuk, additional, Parnis, Francis, additional, Elisei, Rossella, additional, Gajate, Pablo, additional, Gan, Hui K., additional, Kapiteijn, Ellen, additional, Locati, Laura, additional, Mangeshkar, Milan, additional, Faoro, Leonardo, additional, Krajewska, Jolanta, additional, and Jarzab, Barbara, additional

Published
2022
Full Text
View/download PDF

38. B-Raf V600E and thrombospondin-1 promote thyroid cancer progression

Author

Nucera, Carmelo, Porrello, Alessandro, Antonello, Zeus Andrea, Mekel, Michal, Nehs, Matthew A., Giordano, Thomas J., Gerald, Damien, Benjamin, Laura E., Priolo, Carmen, Puxeddu, Efisio, Finn, Stephen, Jarzab, Barbara, Hodin, Richard A., Pontecorvi, Alfredo, Nose, Vânia, Lawler, Jack, Parangi, Sareh, and Donahoe, Patricia K.

Published
2010

43. In Patients With Well-Differentiated Neuroendocrine Tumours, There Is No Apparent Benefit of Somatostatin Analogues After Disease Control By Peptide Receptor Radionuclide Therapy

Author

Syguła, Aleksandra, primary, Ledwon, Aleksandra, additional, Hasse-Lazar, Kornelia, additional, Jurecka-Lubieniecka, Beata, additional, Michalik, Barbara, additional, Paliczka-Cieślik, Ewa, additional, Zeman, Marcin, additional, Chmielik, Ewa, additional, Sczasny, Monika, additional, Jarzab, Barbara, additional, and Handkiewicz-Junak, Daria, additional

Published
2021
Full Text
View/download PDF

44. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

Author

Shi, Xiaoguang, Liu, Rengyun, Basolo, Fulvio, Giannini, Riccardo, Shen, Xiaopei, Teng, Di, Guan, Haixia, Shan, Zhongyan, Teng, Weiping, Musholt, Thomas J., Al-Kuraya, Khawla, Fugazzola, Laura, Colombo, Carla, Kebebew, Electron, Jarzab, Barbara, Czarniecka, Agnieszka, Bendlova, Bela, Sykorova, Vlasta, Sobrinho-Simões, Manuel, Soares, Paula, Shong, Young Kee, Kim, Tae Yong, Cheng, Sonia, Asa, Sylvia L., Viola, David, Elisei, Rossella, Yip, Linwah, Mian, Caterina, Vianello, Federica, Wang, Yangang, Zhao, Shihua, Oler, Gisele, Cerutti, Janete M., Puxeddu, Efisio, Qu, Shen, Wei, Qing, Xu, Huixiong, OʼNeill, Christine J., Sywak, Mark S., Clifton-Bligh, Roderick, Lam, Alfred K, Riesco-Eizaguirre, Garcilaso, Santisteban, Pilar, Yu, Hongyu, Tallini, Giovanni, Holt, Elizabeth H., Vasko, Vasily, and Xing, Mingzhao

Published
2016

45. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Author

Cabanillas, Maria E., Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, McCaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, OʼBrien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., and Ball, Douglas W.

Published
2015
Full Text
View/download PDF

46. Childhood thyroid carcinoma – an experience of one center

Author

Borysewicz-Sańczyk, Hanna, primary, Pasławska, Marta, additional, Zdrodowska, Magdalena, additional, Sawicka, Beata, additional, Pomaski, Janusz, additional, Handkiewicz-Junak, Daria, additional, Krajewska, Jolanta, additional, Czarniecka, Agnieszka, additional, Jarzab, Barbara, additional, Dzieciol, Janusz, additional, and Bossowski, Artur, additional

Published
2021
Full Text
View/download PDF

47. Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015

Author

Czarniecka, Agnieszka, primary, Zeman, Marcin, additional, Wozniak, Grzegorz, additional, Maciejewski, Adam, additional, Stobiecka, Ewa, additional, Chmielik, Ewa, additional, Oczko-Wojciechowska, Malgorzata, additional, Krajewska, Jolanta, additional, Handkiewicz-Junak, Daria, additional, and Jarzab, Barbara, additional

Published
2021
Full Text
View/download PDF

50. B-[Raf.sup.V600E] and thrombospondin-1 promote thyroid cancer progression

Author

Nucera, Carmelo, Porrello, Alessandro, Antonello, Zeus Andrea, Mekel, Michal, Nehs, Matthew A., Giordano, Thomas J., Gerald, Damien, Benjamin, Laura E., Priolo, Carmen, Puxeddu, Efisio, Finn, Stephen, Jarzab, Barbara, Hodin, Richard A., Pontecorvi, Alfredo, Nose, Vania, Lawler, Jack, and Parangi, Sareh

Subjects
Metastasis -- Research, Metastasis -- Development and progression, Metastasis -- Genetic aspects, Thyroid cancer -- Research, Thyroid cancer -- Development and progression, Thyroid cancer -- Genetic aspects, Gene mutations -- Physiological aspects, Gene mutations -- Research, Science and technology
Abstract

Although B-[Raf.sup.V600E] is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressiveness is not fully understood. Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-[Raf.sup.V600E] gene set signature associated with tumor progression in PTCs. An independent cohort of B-[Raf.sup.V600E]-positive PTCs showed significantly higher expression levels of many extracellular matrix genes compared with controls. We performed extensive in vitro and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously shown to be important in the regulation of tumor angiogenesis and metastasis and is present in abundance in tumor stroma. Knockdown of B-[Raf.sup.V600E] resulted in TSP-1 downregulation and a reduction of adhesion and migration/invasion of human thyroid cancer cells. Knockdown of TSP-1 resulted in a similar phenotype. B-[Raf.sup.V600E] cells in which either B-[Raf.sup.V600E] or TSP-1 were knocked down were implanted orthotopically into the thyroids of immunocompromised mice, resulting in significant reduction in tumor size and fewer pulmonary metastases from the primary carcinoma as compared with the control cells. Treatment of orthotopic thyroid tumors, initiated 1 week after tumor cell implantation with PLX4720, an orally available selective inhibitor of B-[Raf.sup.V600E], caused a significant tumor growth delay and decreased distant metastases, without evidence of toxicity. In conclusion, B-[Raf.sup.V600E] plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis. Testing of a patient's thyroid cancer for B-[Raf.sup.V600E] will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-[Raf.sup.V600E] inhibitors, such as PLX4720. extracellular matrix | metastasis | papillary thyroid cancer | tumor microenvironment | cell invasion doi/ 10.1073/pnas.1004934107

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results